Susquehanna International Group, LLP Sellas Life Sciences Group, Inc. Call Options Transaction History

Susquehanna International Group, LLP

14 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 07, 2024	BUY	$0.51 - $1.55 $441,201 - $1.34 Million	865,100 Added 170.43%	1,372,700 $1.39 Million
Q4 2023 Feb 14, 2024	BUY	$0.88 - $1.57 $404,536 - $721,729	459,700 Added 959.71%	507,600 $538,000
Q3 2023 Nov 14, 2023	BUY	$1.42 - $1.83 $5,680 - $7,320	4,000 Added 9.11%	47,900 $78,000
Q2 2023 Aug 11, 2023	SELL	$1.35 - $1.8 $151,200 - $201,600	-112,000 Reduced 71.84%	43,900 $68,000
Q1 2023 May 16, 2023	SELL	$1.18 - $3.86 $152,456 - $498,712	-129,200 Reduced 45.32%	155,900 $222,000

Q4 2022 Feb 14, 2023	BUY	$2.02 - $5.41 $261,186 - $699,513	129,300 Added 82.99%	285,100 $672,000
Q3 2022 Nov 14, 2022	BUY	$2.1 - $3.38 $56,070 - $90,246	26,700 Added 20.68%	155,800 $315,000
Q2 2022 Aug 15, 2022	BUY	$2.14 - $4.15 $178,262 - $345,695	83,300 Added 181.88%	129,100 $288,000
Q1 2022 May 16, 2022	SELL	$4.73 - $7.18 $122,507 - $185,962	-25,900 Reduced 36.12%	45,800 $306,000
Q4 2021 Feb 14, 2022	SELL	$5.36 - $9.53 $540,288 - $960,623	-100,800 Reduced 58.43%	71,700 $397,000
Q3 2021 Nov 15, 2021	BUY	$8.21 - $10.53 $950,718 - $1.22 Million	115,800 Added 204.23%	172,500 $1.58 Million
Q2 2021 Aug 11, 2021	SELL	$7.19 - $13.71 $782,991 - $1.49 Million	-108,900 Reduced 65.76%	56,700 $629,000
Q1 2021 May 17, 2021	BUY	$5.5 - $11.71 $748,550 - $1.59 Million	136,100 Added 461.36%	165,600 $1.41 Million
Q4 2020 Feb 16, 2021	BUY	$2.45 - $17.66 $72,275 - $520,970	29,500 New	29,500 $171,000

8.03M

2.52M

24.7K

Ticker SLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,551,900
Market Cap $24.5M
Description
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.